Reuters - Video

Edition: US | UK | IN | CN | JP

video Business

Breakingviews TV: Gilead growth

Monday, July 15, 2019 - 03:25

The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.

▲ Hide Transcript

View Transcript

The biotech giant is spending $5.1 billion on Belgian outfit Galapagos but won’t take control. That, says Robert Cyran, means Gilead can profit from the smaller drugmaker’s successes, while limiting the risk. It’s a smart move, as both Roche and Sanofi discovered.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Breakingviews TV: Gilead growth

Monday, July 15, 2019 - 03:25